Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 524.46% and ...
BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational ...
Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...